Does co‐treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Abstract

There may be a benefit from adalimumab+immunosuppressive drugs combination therapy during the first semester of initiating adalimumab, with a slight decrease in adalimumab failure and lower need for adalimumab dosage escalation.